The Latest Cardiac and Vascular News
MINNEAPOLIS, May 22, 2025 /PRNewswire/ — Phraxis Inc., a Minneapolis-based medical device company, marks a major milestone with FDA approval of the EndoForce™ Connector for Endovascular Venous Anastomosis (EndoForce™) — a pivotal development in the evolution of dialysis access technology….
In the AVG cohort of the US pivotal trial, the Merit WRAPSODY Cell-Impermeable Endoprosthesis (CIE) achieved 60.2% target lesion primary patency (TLPP) at 12 months. In the AVG cohort of the US pivotal trial, the Merit WRAPSODY Cell-Impermeable Endoprosthesis (CIE) achieved 60.2% target lesion primary patency (TLPP) at 12 months.
AUCKLAND, New Zealand, May 1, 2025 /PRNewswire/ — Soft tissue regeneration company, Aroa Biosurgery, is pleased to announce a milestone in clinical evidence. There are now over 100 peer-reviewed studies describing the efficacy of the company’s proprietary AROA ECM technology. AROA’s most…
Initial 20 Patients Enrolled in the First-in-Human Trial Had a 0% Rate of Reintervention. LOS ALTOS, Calif., April 23, 2025 /PRNewswire/ — The initial long-term results from EFEMORAL I were presented today by Principal Investigator Prof. Andrew Holden (Auckland City Hospital, Auckland, New Zealand) at the Charing Cross Symposium in London, UK. EFEMORAL I is a […]
Baltimore, MD (April 28th, 2025) – Sonavex, Inc., a privately held medical device company with ultrasound technologies that deliver quantitative blood flow and other critical vascular data at the point of care, announced today that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance of the company’s EchoMap™ […]
Vbeam Pro will be unveiled at the 2025 Annual Meeting of American Society for Laser Medicine and Surgery (ASLMS) MARLBOROUGH, Mass., April 24, 2025 /PRNewswire/ — Candela Corporation, a global leader in energy-based medical aesthetics, proudly announced the launch of the Vbeam Pro…
MINNEAPOLIS, April 23, 2025 /PRNewswire/ — VentureMed Group, Inc., a privately held leader in medical device innovations for arteriovenous (AV) access and peripheral arterial disease (PAD), announced data presented at the Charing Cross Symposium, April 23 – 25th, London, England….
European Journal of Vascular and Endovascular Surgery Publishes Results Showing Comparable Safety and Efficacy of SurVeil™ DCB Despite IN.PACT™ Admiral™ DCB having 75% Higher Paclitaxel Dose. Figure 1. SurVeil™ DCB balloon coating (above) vs IN.PACT™ Admiral™ DCB balloon coating (below). EDEN PRAIRIE, Minn.–(BUSINESS WIRE)–Surmodics, Inc. (Nasdaq: SRDX), a leading provider […]
MOUNTAIN VIEW, Calif., April 22, 2025 (GLOBE NEWSWIRE) — R3 Vascular Inc., a medical device company dedicated to developing and providing novel, best-in-class bioresorbable scaffolds for treating peripheral arterial disease (PAD), is pleased to announce that the first patient in its ELITE-BTK pivotal trial was treated by Dr. Brian DeRubertis, FACS, Chief of the Division of Vascular & Endovascular Surgery at New York-Presbyterian and Weill Cornell Medicine in New York City. The trial evaluates R3 Vascular’s next generation drug eluting bioresorbable scaffold, MAGNITUDE®, for below-the-knee (BTK) PAD, which according to the American Heart Association affects more than 200 million people globally, and 10 to 12 million in the U.S. older than the age of 40. The most common type of PAD affects the lower-extremity where blood flow is reduced to the legs and feet. Each year, approximately 150,000 leg amputations are performed in the U.S. alone.
Los Gatos, California – Venova Medical, a privately held company developing a next generation technology for the creation of percutaneous arteriovenous fistulas (pAVF) for hemodialysis access, today announced the successful completion of patient enrollment for the company’s VENOS-2 early feasibility study (NCT06712251). This multi-center study is being performed under an Investigational […]
